Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128997) titled 'SBRT plus Retlirafusp alfa and Chemotherapy as Neoadjuvant Treatment for Resectable NSCLC' on July 29.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: harbin medical university cancer hospital
Condition:
Non-small cell lung cancer (NSCLC), stage II-III, driver gene negative, resectable or potentially resectable
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-08-01
Target Sample Size: Trial group (SBRT followed by Retlirafusp alfa combined with chemotherapy as neoadjuvant therapy ? surgery ? Retlirafusp alfa as adjuvant therapy):44;
Countries of Re...